BiomX Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BiomX Inc. on December 16, 2024. The Company, incorporated in Delaware and headquartered in Ness Ziona, Israel, reports under the trading symbol PHGE on the NYSE American. The filing addresses regulatory compliance status rather than operational or financial performance for a specific fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing status and does not contain financial statements or operational metrics.
Material Changes
The primary material event reported is the resolution of prior listing deficiencies. On December 10, 2024, the Company received notice from the New York Stock Exchange confirming it has regained compliance with all NYSE American continued listing standards. This resolves deficiencies originally raised on May 23, 2024, under Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. Compliance was demonstrated over a period of two consecutive quarters pursuant to Section 1009(f).
Guidance, Outlook, and Risks
The filing includes a Safe Harbor statement regarding forward-looking statements, specifically concerning the Company's ability to maintain compliance with listing standards. Management notes that these statements are based on current beliefs and are subject to uncertainties. Investors are directed to review the "Risk Factors" section of the Company's Annual Report on Form 10-K filed on April 4, 2024, for a comprehensive list of risks and contingencies. No specific financial guidance or outlook was provided in this document.
Key Facts for Investor Verification
- Confirm the Company's continued compliance status on the NYSE American website.
- Review the April 4, 2024, Form 10-K for detailed risk factors and historical financial data.
- Monitor future filings for any new listing deficiency notices or financial performance updates.
- Verify the specific nature of the deficiencies resolved under Sections 1003(a)(i), (ii), and (iii) in prior correspondence.